

iRGD-targeted peptide nanoparticles for anti-angiogenic RNAi-based therapy of endometriosis

Anna Egorova¹, Mariya Petrosyan^{2†}, Marianna Maretina¹, Elena Bazian², Iuliia Krylova³, Vladislav Baranov^{1†} and Anton Kiselev^{1,*}

¹ Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia; A.E. egorova_anna@yahoo.com;

² Pharmacology Group, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia

³ Department of Pathology, Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo Street 6-8, 197022 Saint-Petersburg, Russia

* Correspondence: ankiselev@yahoo.co.uk

† This work is dedicated to memory of our colleagues who passed away in 2022 year

Contents

Figure S1. Silencing of GFP expression after treatment of MDA-MB-231 cells with the siRNA-complexes in presence of 10% fetal bovine serum.....	3
Figure S2. Visual appearance of migrated EA.Hy926 cells after treatment with the siRNA complexes.....	4
Figure S3. Monitoring of animals' weights during experiment in vivo	6






Figure S1. Silencing of GFP expression after treatment of MDA-MB-231 cells with the siRNA-complexes in presence of 10% fetal bovine serum. * - $p < 0.05$ when compared with cells treated by corresponding mock siRNA-complexes. The data are shown as the mean \pm S.E.M.




(a)

(b)




(c)

(d)




(e)

(f)



(g)

(h)






Figure S2. Visual appearance of migrated EA.Hy926 cells after treatment with **(a)** RGD1-R6/anti-VEGFA siRNA at N/P ratio 8/1 **(b)** RGD1-R6/mock siRNA at N/P ratio 8/1, **(c)** RGD1-R6/anti-VEGFA at N/P ratio 16/1, **(d)** RGD1-R6/mock siRNA at N/P ratio 16/1, **(e)** RGD0-R6/anti-VEGFA at N/P ratio 8/1, **(f)** RGD0-R6/mock siRNA at N/P ratio 8/1, **(g)** RGD0-R6/anti-VEGFA at N/P ratio 16/1, **(h)** RGD0-R6/mock siRNA at N/P ratio 16/1, **(i)** x-tremeGENE/anti-VEGFA siRNA, **(j)** x-tremeGENE/mock siRNA, **(k)** naked anti-VEGFA siRNA, **(l)** mock siRNA.




Figure S3. Monitoring of animals' weights during experiment in vivo.